Literature DB >> 25296721

Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis.

Jan Halbritter1, Michelle Baum1, Ann Marie Hynes2, Sarah J Rice3, David T Thwaites4, Zoran S Gucev5, Brittany Fisher1, Leslie Spaneas1, Jonathan D Porath1, Daniela A Braun1, Ari J Wassner6, Caleb P Nelson7, Velibor Tasic5, John A Sayer8, Friedhelm Hildebrandt9.   

Abstract

Nephrolithiasis is a prevalent condition with a high morbidity. Although dozens of monogenic causes have been identified, the fraction of single-gene disease has not been well studied. To determine the percentage of cases that can be molecularly explained by mutations in 1 of 30 known kidney stone genes, we conducted a high-throughput mutation analysis in a cohort of consecutively recruited patients from typical kidney stone clinics. The cohort comprised 272 genetically unresolved individuals (106 children and 166 adults) from 268 families with nephrolithiasis (n=256) or isolated nephrocalcinosis (n=16). We detected 50 likely causative mutations in 14 of 30 analyzed genes, leading to a molecular diagnosis in 14.9% (40 of 268) of all cases; 20 of 50 detected mutations were novel (40%). The cystinuria gene SLC7A9 (n=19) was most frequently mutated. The percentage of monogenic cases was notably high in both the adult (11.4%) and pediatric cohorts (20.8%). Recessive causes were more frequent among children, whereas dominant disease occurred more abundantly in adults. Our study provides an in-depth analysis of monogenic causes of kidney stone disease. We suggest that knowledge of the molecular cause of nephrolithiasis and nephrocalcinosis may have practical implications and might facilitate personalized treatment.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  Bartter syndrome; human genetics; hypercalciuria; kidney stones; molecular genetics; renal tubular acidosis

Mesh:

Year:  2014        PMID: 25296721      PMCID: PMC4341487          DOI: 10.1681/ASN.2014040388

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  30 in total

1.  Genomic organization of a human cystine transporter gene (SLC3A1) and identification of novel mutations causing cystinuria.

Authors:  J K Endsley; J A Phillips; K A Hruska; T Denneberg; J Carlson; A L George
Journal:  Kidney Int       Date:  1997-06       Impact factor: 10.612

2.  Cystine: a promoter of the growth and aggregation of calcium oxalate crystals in normal undiluted human urine.

Authors:  Maria C Martins; Anthony A Meyers; Natalie A Whalley; Allen L Rodgers
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

3.  Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele.

Authors:  Carla G Monico; Sandro Rossetti; Julie B Olson; Dawn S Milliner
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

4.  Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24.

Authors:  B Y Reed; H J Heller; W L Gitomer; C Y Pak
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

5.  SLC7A9 mutations in all three cystinuria subtypes.

Authors:  Daniel Leclerc; Marylise Boutros; Daniel Suh; Qing Wu; Manuel Palacin; James R Ellis; Paul Goodyer; Rima Rozen
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

6.  Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes.

Authors:  Elke Botzenhart; Udo Vester; Christa Schmidt; Albrecht Hesse; Marc Halber; Carsten Wagner; Florian Lang; Peter Hoyer; Klaus Zerres; Thomas Eggermann
Journal:  Kidney Int       Date:  2002-10       Impact factor: 10.612

7.  Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias.

Authors:  Gill Rumsby; Emma Williams; Marion Coulter-Mackie
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

8.  Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption.

Authors:  D B Simon; Y Lu; K A Choate; H Velazquez; E Al-Sabban; M Praga; G Casari; A Bettinelli; G Colussi; J Rodriguez-Soriano; D McCredie; D Milford; S Sanjad; R P Lifton
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

9.  Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria.

Authors:  M A Font; L Feliubadaló; X Estivill; V Nunes; E Golomb; Y Kreiss; E Pras; L Bisceglia; A P d'Adamo; L Zelante; P Gasparini; M T Bassi; A L George ; M Manzoni; M Riboni; A Ballabio; G Borsani; N Reig; E Fernández; A Zorzano; J Bertran; M Palacín
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

10.  Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine.

Authors:  M J Calonge; P Gasparini; J Chillarón; M Chillón; M Gallucci; F Rousaud; L Zelante; X Testar; B Dallapiccola; F Di Silverio
Journal:  Nat Genet       Date:  1994-04       Impact factor: 38.330

View more
  74 in total

Review 1.  Exploring the genetic basis of early-onset chronic kidney disease.

Authors:  Asaf Vivante; Friedhelm Hildebrandt
Journal:  Nat Rev Nephrol       Date:  2016-01-11       Impact factor: 28.314

2.  Personalized medicine in chronic kidney disease by detection of monogenic mutations.

Authors:  Dervla M Connaughton; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

3.  A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass.

Authors:  Pietro Manuel Ferraro; Angelo Minucci; Aniello Primiano; Elisa De Paolis; Jacopo Gervasoni; Silvia Persichilli; Alessandro Naticchia; Ettore Capoluongo; Giovanni Gambaro
Journal:  Urolithiasis       Date:  2016-09-17       Impact factor: 3.436

4.  Evidence for epistatic interaction between VDR and SLC13A2 genes in the pathogenesis of hypocitraturia in recurrent calcium oxalate stone formers.

Authors:  Domenico Rendina; Gianpaolo De Filippo; Fernando Gianfrancesco; Riccardo Muscariello; Michele Schiano di Cola; Pasquale Strazzullo; Teresa Esposito
Journal:  J Nephrol       Date:  2016-09-17       Impact factor: 3.902

5.  Targeted renal knockdown of Na+/H+ exchanger regulatory factor Sip1 produces uric acid nephrolithiasis in Drosophila.

Authors:  Saurav Ghimire; Selim Terhzaz; Pablo Cabrero; Michael F Romero; Shireen A Davies; Julian A T Dow
Journal:  Am J Physiol Renal Physiol       Date:  2019-07-31

Review 6.  Recent advances in the identification and management of inherited hyperoxalurias.

Authors:  David J Sas; Peter C Harris; Dawn S Milliner
Journal:  Urolithiasis       Date:  2018-12-10       Impact factor: 3.436

7.  Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.

Authors:  Karl P Schlingmann; Justyna Ruminska; Martin Kaufmann; Ismail Dursun; Monica Patti; Birgitta Kranz; Ewa Pronicka; Elzbieta Ciara; Teoman Akcay; Derya Bulus; Elisabeth A M Cornelissen; Aneta Gawlik; Przemysław Sikora; Ludwig Patzer; Matthias Galiano; Veselin Boyadzhiev; Miroslav Dumic; Asaf Vivante; Robert Kleta; Benjamin Dekel; Elena Levtchenko; René J Bindels; Stephan Rust; Ian C Forster; Nati Hernando; Glenville Jones; Carsten A Wagner; Martin Konrad
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

8.  Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones.

Authors:  Carmen Inés Rodriguez Cuellar; Peter Zhan Tao Wang; Michael Freundlich; Guido Filler
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

9.  APRT deficiency: the need for early diagnosis.

Authors:  Aamira Huq; Kushma Nand; Rajiv Juneja; Ingrid Winship
Journal:  BMJ Case Rep       Date:  2018-10-23

Review 10.  How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Authors:  Kim Hovgaard Andreassen; Katja Venborg Pedersen; Susanne Sloth Osther; Helene Ulrik Jung; Søren Kissow Lildal; Palle Joern Sloth Osther
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.